11th International Symposium on Minimal Residual Cancer (ISMRC): 3–5 May 2018, Montpellier, France

Alix‐Panabières, Catherine; Pantel, Klaus

doi:10.1007/s10585-018-9909-7

Cited by 1 publication

(1 citation statement)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, although the optimum CTC threshold can stratify patients into high-risk and low-risk subgroups, whether the former benefit from AT needs to be confirmed in a further clinical trial. Third, liquid biopsy is in a period of vigorous development, 50 and currently, there is still no perfect method for detecting CTCs in lung cancer.…”

Section: Discussionmentioning

confidence: 99%

Clinical Significance of a Circulating Tumor Cell-based Classifier in Stage IB Lung Adenocarcinoma

et al. 2023

View full text Add to dashboard Cite

To investigate the effectiveness of a CTC-based classifier in stratifying stage IB LUAD. Summary of Background Data: Stage IB LUADs have an approximately 70% 5-year survival rate. The clinical application of ACT is controversial due to inconsistent results in a series of trials and few useful guide biomarkers. Thus, there is a pressing need for robust biomarkers to stratify stage IB patients to define which group would most likely benefit from ACT. Methods: Two hundred twelve stage IB LUAD patients were enrolled and were divided into 3 independent cohorts. The aptamermodified NanoVelcro system was used to enrich the CTCs. Results: A cutoff of < 4 or > 4 CTCs as the optimal prognostic threshold for stage IB LUAD was generated to stratify the patients in a 70-patient cohort into low-risk and high-risk groups. Patients with ≥ 4 CTCs in the training cohort had shorter progression-free survival (P < 0.0001) and overall survival (P < 0.0001) than patients with < 4 CTCs. CTC number remained the strongest predictor of progression-free survival and overall survival even in a multivariate analysis including other clinicopathological parameters. Furthermore, a nomogram based on the CTC count was developed to predict the 3-year and 5-year survival in the training cohort and performed well in the other 2 validation cohorts (C-index: 0.862, 0.853, and 0.877). Conclusion:The presence of > 4 CTCs can define a high-risk subgroup, providing a new strategy to make optimal clinical decisions for stage IB LUAD.

show abstract

Section: Discussionmentioning

confidence: 99%